重度盆腔子宫内膜异位症腹腔镜术后应用米非司酮与内美通156例临床分析

目的:探讨米非司酮及内美通用于重度盆腔子宫内膜异位症(内异症)腹腔镜术后辅助药物治疗的疗效及安全性。方法:回顾分析了156例重度盆腔子宫内异症患者腹腔镜术后随访资料,比较术后应用米非司酮、内美通及未用药组的复发率和副反应发生率。结果:米非司酮组、内美通组复发率分别为13.6%、11.1%,低于未用药组34.6%(P<0.05,P<0.05)。米非司酮组副反应发生率11.9%,显著低于内美通组44.4%(P<0.05)。结论:米非司酮、内美通用于盆腔子宫内异症腹腔镜术后的治疗,能显著地降低内异症的复发率,提高妊娠率,且米非司酮副反应较少。

The clinical analysis of 156 cases on the effects of mifepristone and gestrinone treatment for postoperative patients with severe pelvic endometriosis

Objective:To investigate the effects and safety of mifepristone and gestrinone for treating for postoperative patients with severe pelvic endometriosis.Methods:156 severe pelvic endometriosis cases were analyzed retrospectively . Of the cases , 59 cases were administered mifepristone , 45 cases were administered gestrinone and other 52 cases had not taken any hormone . Recurrence rate , side effect rate were compared among these groups.Results:The recurrence rate of mifepristone group and gestrinone group was 13.6% and 11.1% , respectively , which was significantly lower than that of control group(P<0.05,P<0.05).The side effect rate of mifepristone group was 11.9% , which was significantly lower than that of gestrinone group(44.4%)(P<0.05).Conclusion:The treatment of mifepristone and gestrinone treatment on postoperative patients with pelvic endometriosis can significantly decreased the recurrence rate of pelvic endometriosis , and elevate pregnancy rate . Mifepristone has less side effects than that of gestrinone .